These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 28980665)
1. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease. Holmes MV; Smith GD Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665 [TBL] [Abstract][Full Text] [Related]
2. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both. Nicholls SJ Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215 [TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Shinkai H Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899 [TBL] [Abstract][Full Text] [Related]
12. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288 [TBL] [Abstract][Full Text] [Related]
13. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Karalis I; Rensen PC; Jukema JW Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310 [No Abstract] [Full Text] [Related]
14. Trials and Tribulations of CETP Inhibitors. Tall AR; Rader DJ Circ Res; 2018 Jan; 122(1):106-112. PubMed ID: 29018035 [TBL] [Abstract][Full Text] [Related]
15. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease? Nicholls SJ; Nelson AJ Am J Cardiovasc Drugs; 2019 Jun; 19(3):229-235. PubMed ID: 30610681 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic targets to raise HDL in patients at risk or with coronary artery disease. Lüscher TF; von Eckardstein A; Simic B Curr Vasc Pharmacol; 2012 Nov; 10(6):720-4. PubMed ID: 23259565 [TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987 [TBL] [Abstract][Full Text] [Related]
20. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]